Compare TCMD & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCMD | JCE |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 247.6M |
| IPO Year | 2016 | 2007 |
| Metric | TCMD | JCE |
|---|---|---|
| Price | $26.34 | $14.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | ★ 231.3K | 33.8K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.14 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | $9.14 | N/A |
| P/E Ratio | $32.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.61 | $12.51 |
| 52 Week High | $37.77 | $16.31 |
| Indicator | TCMD | JCE |
|---|---|---|
| Relative Strength Index (RSI) | 39.65 | 22.87 |
| Support Level | $25.79 | N/A |
| Resistance Level | $26.57 | $15.88 |
| Average True Range (ATR) | 0.98 | 0.27 |
| MACD | -0.11 | -0.08 |
| Stochastic Oscillator | 23.22 | 1.68 |
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.